Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

PHASE4TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Aspergillosis
Interventions
DRUG

voriconazole

Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).

DRUG

anidulafungin

Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy

Trial Locations (4)

30322

Pfizer Investigational Site, Atlanta

48202

Pfizer Investigational Site, Detroit

76104

Pfizer Investigational Site, Fort Worth

76107

Pfizer Investigational Site, Fort Worth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00620074 - Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) | Biotech Hunter | Biotech Hunter